# Infectious Diseases (tuberculosis) Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Higuchi Ichiyō (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI029-SYN
- Date: 2026-04-17
- Fictional facility: St. Posthumous Health Center
- Fictional author: Hiroshi Abernathy-Okoye, MD
- Calendar frame: modern shifted

- Requested by: Aiko Lindgren-Tanaka, MD

## Reason for consultation

Suspected pulmonary tuberculosis in a 23-year-old writer with seven weeks of cough, evening fevers, night sweats and 10 percent weight loss, and right upper lobe opacities without a cavity. Please see her at the results visit in three days to confirm the diagnosis, choose the regimen and doses, and advise on monitoring and infection control. **S**

## History

Ms. Higuchi, a 23-year-old writer, is seen at the request of Dr. Lindgren-Tanaka at her results visit three days after her first visit. She describes about seven weeks of cough with a little white sputum, evening fevers, night sweats and weight loss, and she has been too tired to write for more than an hour or two. She has no hemoptysis, no known tuberculosis contact, no travel outside Japan, and no condition or medicine that weakens the immune system. She does not smoke or drink and takes no medicines. She lives with two adults and has stayed home with a mask in shared rooms since her first visit. She is anxious about the people she lives with and about the cost of treatment. **S**

## Examination

| System | Finding |
|---|---|
| General | Thin and tired; temperature 37.6 °C, pulse 100; seen in an airborne infection isolation room |
| Respiratory | Fine crackles over the right upper zone |
| Eyes | No icterus |
| Abdomen | Liver not enlarged |

BP 96/60 mmHg; pulse 100 bpm; respirations 20/min; temperature 37.6 °C; oxygen saturation 96% on room air; weight 38.4 kg; BMI 17.5 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Lindgren-Tanaka's intake note and results. Chest X-ray: right upper lobe opacities and small nodules without a cavity. Three sputum specimens, one on waking: smears negative for acid-fast bacilli; Xpert MTB/RIF Ultra on the first specimen detected Mycobacterium tuberculosis at a low level with no rifampin resistance; cultures pending. HIV antigen and antibody test, hepatitis B surface antigen and core antibody, hepatitis C antibody and pregnancy test negative; hepatitis B surface antibody negative. Liver and kidney tests normal; albumin 3.3 g/dL; hemoglobin 11.4 g/dL; hemoglobin A1c 5.1%. Visual acuity 85 letters in each eye; color vision normal. Weight today 38.4 kg. 

## Assessment

1. **Pulmonary tuberculosis, smear-negative, Xpert-confirmed** (A15.0). A positive Xpert MTB/RIF Ultra result in a patient with this history and X-ray confirms pulmonary tuberculosis even with negative smears; treatment should start today and not wait for culture. No rifampin resistance was detected and she has no risk factors for drug resistance. Smear-negative disease without a cavity carries a lower bacterial load and a lower risk of transmission. **S**
2. **Regimen choice** (A15.0). The four-month rifapentine-moxifloxacin regimen requires a body weight of at least 40 kg, and she weighs 38.4 kg, so she is not eligible; the standard six-month regimen is recommended. Doses: isoniazid 200 mg (about 5 mg/kg), rifampin 450 mg (about 12 mg/kg, within the WHO range of 8 to 12 mg/kg, using 150 mg capsules), pyrazinamide 1000 mg (about 26 mg/kg) and ethambutol 600 mg (about 16 mg/kg), with pyridoxine because of her poor nutrition. Doses are reviewed if her weight changes by more than about 5 kg. **S**
3. **Moderate malnutrition and liver risk** (E44.0). Low weight and albumin raise the risk of drug-induced liver injury, so liver tests at two weeks and monthly in the intensive phase are advised, in addition to symptom checks at every observed dose. If tests stay normal and albumin recovers, testing in the continuation phase can be for symptoms only. **S**

## Recommendations

1. Start isoniazid 200 mg, rifampin 450 mg, pyrazinamide 1000 mg, ethambutol 600 mg and pyridoxine 50 mg daily today, by daily video-observed therapy with the public health center.
2. Outpatient treatment is appropriate for smear-negative disease without a cavity in a patient who can stay home; continue home precautions until she has had two weeks of treatment and is improving, then end them with the public health center's agreement.
3. Liver tests at two weeks and monthly in the intensive phase; visual acuity and color vision at two weeks and monthly while on ethambutol; stop the drugs and call the same day for hepatitis symptoms or any change in vision.
4. Stop ethambutol as soon as the isolate is shown to be susceptible to isoniazid and rifampin.
5. Sputum smear and culture at two weeks and at two months; without a cavity the continuation phase is four months of isoniazid and rifampin; consider seven months if the two-month culture is positive, because she is underweight.
6. Notify the public health center at once on diagnosis; its contact investigation should cover the household first, then other close contacts with hours of shared indoor air during the infectious period, such as visiting editors.
7. Counsel her that rifampin makes hormonal contraceptives unreliable and interacts with many medicines; avoid fluoroquinolones for other infections during treatment.
8. Chest X-ray at the end of treatment as a new baseline.

## Strengths and supports

- Supports and strengths she names: her writing, her readers and editors, and the poetry she studied when young **S**

## Communication

Discussed with Dr. Lindgren-Tanaka the same morning; she continues the prescribing and monitoring with the public health center. Ms. Higuchi was told that tuberculosis is curable with six months of treatment, that she will soon stop being infectious, and that most of the costs are covered by public funding; she asked how soon she could write again and was encouraged to begin with short sessions once the fevers settle. **S**

## Follow-up

Available by phone to Dr. Lindgren-Tanaka for the susceptibility results and any adverse effect; review again if a drug has to be stopped. **S**

## Guideline basis

- Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016), American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America (Clinical Infectious Diseases 2016;63(7):e147-e195)
- Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline (2025), American Thoracic Society, Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America (American Journal of Respiratory and Critical Care Medicine 2025;211(1):15-33)
- WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment (2022), World Health Organization
- Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children (2017), American Thoracic Society, Infectious Diseases Society of America, and Centers for Disease Control and Prevention (Clinical Infectious Diseases)
- Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022 (2022), Centers for Disease Control and Prevention (MMWR)
- An official ATS statement: hepatotoxicity of antituberculosis therapy (2006), American Thoracic Society (American Journal of Respiratory and Critical Care Medicine)
- Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
- 結核 (Tuberculosis): notification criteria under Article 12 of the Infectious Diseases Control Law (current), Ministry of Health, Labour and Welfare, Japan
